Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 9/20 | 0.61 |
| ▸ | F13A1 | P00488 | 6/20 | 0.61 |
| ▸ | TGM1 | P22735 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | LIPE | Q05469 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18153290 | 0.86 | PKM (0.66) | TGM2F13A1TGM1PKM | |
| SCHEMBL18702188 | 0.86 | EPHX2 (0.53) | PKMSMN1; SMN2EPHX2LIPESCN9A | |
| SCHEMBL25296793 | 0.86 | LIPE (0.46) | TGM2F13A1TGM1EPHX2GPR119 | |
| SCHEMBL29076533 | 0.85 | EPHX2 (0.52) | PKMSMN1; SMN2EPHX2LIPESCN9A | |
| SCHEMBL309243 | 0.85 | TGM2 (0.64) | TGM2F13A1TGM1PKMEPHX2 | |
| SCHEMBL18711920 | 0.85 | MEN1 (0.55) | PKMSMN1; SMN2EPHX2LIPESCN9A | |
| SCHEMBL1181084 | 0.85 | PKM (0.73) | TGM2F13A1TGM1PKM | |
| SCHEMBL22032771 | 0.84 | TGM2 (0.60) | TGM2F13A1TGM1PKMSMN1; SMN2 | |
| SCHEMBL18410584 | 0.83 | TGM2 (0.65) | TGM2F13A1TGM1PKMSMN1; SMN2 | |
| SCHEMBL1106926 | 0.83 | TGM2 (0.59) | TGM2F13A1TGM1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| EP-2533782-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2012-12-19 | — | — | EP | disclosed |
| CN-1930139-B | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS OXFORD LTD | 2011-07-27 | — | — | CN | disclosed |
| WO-2011086377-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086377-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-07-21 | — | — | WO | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| CN-1930139-A | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS OXFORD LTD (GB) | 2007-03-14 | — | — | CN | disclosed |
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1660471-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019194-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LIMITED (GB) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019194-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LIMITED (GB) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CACNA1B, CACNB2, CACNA1C | TGM2 2022/4885F13A1 3540/4885TGM1 2831/4885 |
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | MMP13, MMP3, MMP1 | TGM2 2279/4885F13A1 707/4885TGM1 2260/4885 |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | MMP3, MMP1, MMP13 | TGM2 898/4885F13A1 235/4885TGM1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.